Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide PK with Oral Contraceptives in Obesity or Overweight
NCT07808060Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eloralintide in obesity, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve from Time Zero to Infinity at Day 128, Maximum Concentration at Day 128 and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07808060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808060.